We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Trial to Evaluate the Efficacy of Low Dose Vaginal Estrogens in the Treatment of Atrophic Vaginitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00816556
Recruitment Status : Terminated (Funding)
First Posted : January 1, 2009
Results First Posted : March 28, 2014
Last Update Posted : November 13, 2017
Sponsor:
Collaborator:
Information provided by (Responsible Party):

Study Description
Brief Summary:

Atrophic vaginitis is a common problem that occurs in up to 40% of postmenopausal women. The main symptoms are dryness, itching and burning in and around the vagina. These symptoms in turn can cause pain with intercourse. Other symptoms can include urinary frequency and urinary urgency. These symptoms are caused by the decreasing levels of estrogens in postmenopausal women.

The current treatment options include hormone replacement therapy by mouth and patch and vaginal creams, tablets and rings. The current guideline recommend using hormone therapy at the lowest dose for the shortest time. We are trying to find the lowest effective dose of estrogen cream that helps with symptoms without causing an increase in estrogens in the blood stream.

We want to compare two estrogen creams, estradiol and estriol, each at very low doses, with a placebo cream. Estradiol cream is available on prescription but we want to see how effective it is at one tenth the commonly prescribed dose. Estriol cream is not commonly prescribed and is only available at compounding pharmacies. We want to see if either of these estrogens is effective at one tenth the usual dose. We also want to see if these creams are effective when massaged onto the outer part of the vagina, rather than the usual method of treatment, which is inserting them into the vagina.


Condition or disease Intervention/treatment Phase
Atrophic Vaginitis Drug: Estriol Drug: Estradiol valerate Drug: Vanicream Lite Phase 3

Detailed Description:
This trial will measure the effects of very low doses of estradiol or estriol cream applied to the vaginal introitus for the treatment of atrophic vaginitis, a common condition affecting up to 40% of postmenopausal women. We will conduct a randomized controlled trial with three arms-estradiol, estriol and placebo. The intervention will last for 12 weeks. The outcomes we will be most interested in are the efficacy of the treatments for symptoms of atrophic vaginitis compared to placebo and whether there is any measurable systemic absorption from the locally applied estrogen creams. These outcomes will be measured, primarily, by the use of patient questionnaires and secondarily, clinical examination scores. Safety will be evaluated with serum estrogen concentrations. All measures will be collected at baseline and at the termination of the study. Hormone concentrations will be collected, additionally, at week 2. This trial will answer important questions regarding the impact of very low doses of locally applied estrogens and symptoms of atrophic vaginitis. It will provide information on effect size and validity of outcome measures. It will also give information about whether low doses of estrogen creams, locally applied to the vaginal introitus, result in systemic absorption

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 63 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized Controlled Trial to Evaluate the Efficacy of Low Dose Vaginal Estrogens in the Treatment of Atrophic Vaginitis
Study Start Date : October 2008
Primary Completion Date : September 2011
Study Completion Date : December 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Vaginitis
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Active Comparator: Estriol
Estriol 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks
Drug: Estriol
Estriol 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for 2 weeks and then twice weekly for 10 weeks.
Active Comparator: Estradiol
Estradiol valerate 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks
Drug: Estradiol valerate
Estradiol valerate 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks
Other Name: Delestrogen
Placebo Comparator: Vanicream Lite
Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks
Drug: Vanicream Lite
Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks


Outcome Measures

Primary Outcome Measures :
  1. Change in Vulvovaginal Atrophy Questionnaire (VVAQ) Scores From Baseline to Week 12 [ Time Frame: baseline, 12 weeks ]
    The VVAQ consists of three questions asking the participant to rate the severity and how bothersome each of the symptoms of atrophic vaginitis are (dryness, itching, and burning). It is graded 0 through 10. A higher number indicates less severe and less bothersomeness of the symptom, that is, 0= very severe or bothersome, 10= least severe or bothersome.


Secondary Outcome Measures :
  1. Change in Serum Estrone (E1) Levels Between Baseline, 2 Weeks, and 12 Weeks [ Time Frame: baseline, 2 weeks, 12 weeks ]
  2. Change in Serum Estradiol (E2) Levels Between Baseline, 2 Weeks, and 12 Weeks [ Time Frame: baseline, 2 weeks, 12 weeks ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   40 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Postmenopausal women (no menses for the previous 12 months)
  • Dryness, itching or burning in and around the vagina
  • Discontinued hormone replacement therapy (either local or systemic) at least 3 months

Exclusion Criteria:

  • Known, suspected, or history of cancer of the breast.
  • Known, or suspected estrogen dependent neoplasia (ovarian, endometrial).
  • Known hypersensitivity to any component of the medications or base creams.
  • Active deep vein thrombosis, pulmonary embolism, or history of these conditions.
  • Active or recent (within the past year) arterial thromboembolic disease (stroke, myocardial infarct).
  • Liver dysfunction or disease with elevation of aspartate aminotransferase (AST)>1.5x upper level of normal (ULN); Normal for females is 8-43 U/L.
  • Undiagnosed abnormal genital bleeding.
  • Known chronic lichen sclerosis.
  • Known, untreated vaginal infection.
  • Not had a normal screening mammogram within the last 15 months.
  • Hysterectomy without oophorectomy unless 60 years or older.
  • Women taking aromatase inhibitors or tamoxifen.
  • Hgb <12.0 or >15.5 g/dL
  • Urinalysis showing a urinary tract infection (UTI).
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00816556


Locations
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Maire Mac Bride
National Center for Advancing Translational Science (NCATS)
Investigators
Principal Investigator: Maire B Mac Bride, MB BCh Mayo Clinic
More Information

Additional Information:
Responsible Party: Maire Mac Bride, M.B., B. Ch., Assistant Professor of Medicine, College of Medicine, Mayo Clinic
ClinicalTrials.gov Identifier: NCT00816556     History of Changes
Other Study ID Numbers: 07-008730
UL1TR000135 ( U.S. NIH Grant/Contract )
First Posted: January 1, 2009    Key Record Dates
Results First Posted: March 28, 2014
Last Update Posted: November 13, 2017
Last Verified: October 2017

Additional relevant MeSH terms:
Pathological Conditions, Anatomical
Vaginal Diseases
Genital Diseases, Female
Atrophy
Vaginitis
Atrophic Vaginitis
Estradiol
Polyestradiol phosphate
Estrogens
Estradiol 3-benzoate
Estradiol 17 beta-cypionate
Estradiol valerate
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Contraceptive Agents
Reproductive Control Agents
Contraceptive Agents, Female